OncoMatch/Clinical Trials/NCT06710756

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Is NCT06710756 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 for pancreatic ductal adenocarcinoma.

Phase 1/2RecruitingPerspective TherapeuticsNCT06710756Data as of May 2026

Treatment: [203Pb]Pb-PSV359 · [212Pb]Pb-PSV359 — Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Gastric Cancer

Esophageal Carcinoma

Colorectal Cancer

Ovarian Cancer

Head and Neck Squamous Cell Carcinoma

Sarcoma

Mesothelioma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: systemic anticancer therapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Saint Louis University · St Louis, Missouri
Nebraska Cancer Specialists · Omaha, Nebraska
University of Pittsburgh Medical Center · Pittsburgh, Pennsylvania

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify